Royalty Pharma
Royalty Pharma

Royalty Pharma

Pharmaceuticals
WebsiteInvestor RelationsSEC
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

$30.7B

Market Cap • 11/12/2026

1996

(30 years)

Founded

2020

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

4,5

P/S

15,2

P/EBITDA

20,5

P/OCF

13,5

P/FCF

13,5

P/E

45,1

BVPS

15,4

EPS

1,2

Market Cap

Market Cap

30,7B

EV

47,9B

EV/Revenue

18,3

EV/EBITDA

31,9

EV/EBIT

32

Payout

Dividend Per Share

0,9

Dividend Yield

1,3%

Buyback Yield

0,7%

Total Yield

2%

Dividend Yield 5Y

2,3%

Payout

60,8%

Retained Earnings

2,5B

Profitability

Gross Margin

100%

EBITDA Margin

57,3%

EBIT Margin

57,1%

Net Margin

44,8%

D&A/EBITDA

0%

R&D/Revenue

9,6%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

15,5%

% PPE

0%

% Goodwill

4,7%

ROE

12,1%

ROIC

8%

Growth

CAGR Revenue 5Y

2,7%

CAGR Op. Income 5Y

-1,2%

CAGR Net Income 5Y

-5,5%

CAGR EPS 5Y

-4,6%

CAGR OCF 5Y

7,2%

Leverage

N.D./EBITDA

5,4

Debt/Equity

0%

Current Ratio

1,3

Quick Ratio

0,5

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium